Axa
KYTH

Axa’s KYTHERA BIOPHARMACEUTICALS, INC COM KYTH Stock Holding History

Axa’s Portfolio KYTH Stock Details KYTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-6,761
Closed -$509K – 1556
2015
Q2 		$509K Buy
+6,761
New +$362K ﹤0.01% 1080
2014
Q2 		– Sell
-13,335
Closed -$530K – 1476
2014
Q1 		$530K Buy
+13,335
New +$597K ﹤0.01% 1054

Other funds holding KYTH

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Axa's KYTH Position: Q3 2015 in Review

Axa sold out of KYTHERA BIOPHARMACEUTICALS, INC COM (KYTH) in Q3 2015, closing a stake of 6,761 shares — an estimated $509K sold.

Axa first reported a position in KYTH in Q1 2014 and held it in 2 quarters. The position peaked at $530K in Q1 2014. 143 funds tracked by Wall St. Rank hold KYTH as of Q3 2015.

  • Axa reported no remaining KYTHERA BIOPHARMACEUTICALS, INC COM position as of Q3 2015 after selling out during the quarter.
  • Axa sold 6,761 KYTHERA BIOPHARMACEUTICALS, INC COM shares in Q3 2015, an estimated $509K.
  • Axa first reported a position in KYTHERA BIOPHARMACEUTICALS, INC COM in Q1 2014 and held it in 2 quarters.
  • Axa's KYTHERA BIOPHARMACEUTICALS, INC COM position peaked at $530K in Q1 2014.
  • 143 funds tracked by Wall St. Rank held KYTHERA BIOPHARMACEUTICALS, INC COM as of Q3 2015.

Based on Axa's 13F filing for Q3 2015, filed 13 Nov 2015.